Redcare Pharmacy Faces a Two-Sided Coin: Upgraded Forecasts Meet Rossmann’s Rx Ambitions

Redcare Pharmacy shares hold steady after June surge, but a new rival Rossmann enters the Rx market, testing the stock's uptrend ahead of half-year results.

Redcare Pharmacy’s stock is settling into a holding pattern, caught between the tailwinds of a recent guidance upgrade and the fresh headwind of a deep-pocketed new competitor. The shares closed at €66.05 on Friday, a modest 0.38% gain for the session, but the weekly performance tells a more cautious story with a 1.42% decline.

The consolidation follows a dramatic June, when the stock surged roughly 43% after management raised its 2026 revenue growth forecast from 13-15% to 15-17%. That rally, however, included a sharp intra-week jolt: a single-day drop of 3.87% on Thursday that analysts view as a technical breather rather than a fundamental shift. The shares now trade about 15% above their 200-day moving average of €57.41, a sign the medium-term uptrend remains intact, while the 14-day RSI at 52.9 leaves room for movement in either direction without signaling overbought or oversold conditions.

The Rx Growth Engine and a New Rival

The heart of Redcare’s upgraded outlook lies in its German prescription drug (Rx) business. The company now targets Rx revenues between €680 million and €720 million, representing potential growth of 35% to 43%. This ambition comes as Germany’s electronic prescription system gains traction, and Redcare has secured an extension of its CardLink license through January 2027, keeping its foothold in the digital prescription market even as new “proof of patient presence” technologies emerge.

But the competitive landscape just got more crowded. On Friday, German drugstore chain Rossmann announced the launch of its own online pharmacy for prescription medications, shipping from the same Dutch city of Emmen that Redcare uses. Rossmann brings a formidable digital asset: roughly 12 million active app users, which it can leverage to funnel e-prescriptions directly into its ecosystem. This move signals that the battle for Rx market share is entering a new phase, and Redcare’s path to its €720 million target now runs through a well-capitalized rival with an existing customer base.

Market Consolidation Creates Opportunity

The Rossmann entry contrasts with ongoing consolidation among smaller players. On July 15, German competitor Sanicare filed for insolvency in self-administration for the second time, despite generating around €80 million in annual revenue in 2025. The company struggled with declining sales and the high costs of IT infrastructure and logistics — a burden that industry observers say is squeezing traditional mail-order pharmacies as digitalization raises the investment bar.

Redcare’s scale advantages may help it weather these pressures better than smaller rivals, but the Rossmann challenge is of a different magnitude. The drugstore chain’s existing retail footprint and digital reach could allow it to capture market share quickly, particularly among customers already familiar with its brand.

What’s Next: Half-Year Results as the Litmus Test

The stock’s near-term direction hinges on the half-year results due at the end of July. Investors will scrutinize whether the upgraded guidance has operational substance, particularly the adjusted EBITDA margin target of 2.5% to 3.0%. Any deviation from the Rx growth range could trigger an immediate share price reaction, and management’s commentary on marketing efficiency in the DACH region will also be closely watched.

The broader regulatory backdrop remains complex. GKV Spitzenverband chief Oliver Blatt recently highlighted a funding gap of roughly €4 billion in Germany’s statutory health insurance system, which could lead to future adjustments in patient co-payments. Meanwhile, pharmacy associations continue to push for tighter regulation of foreign online providers, adding another layer of uncertainty.

For now, the stock sits well below its 52-week high of €112.10 set on July 25, 2025 — a gap of over 40% that underscores how far the shares have fallen from their peak. Whether the upgraded Rx targets and the Sanicare consolidation can offset the Rossmann threat will determine if the current stabilization phase gives way to a sustained recovery or merely a pause before further pressure.